Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Background & Aims Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients. Methods A systematic search o...
Saved in:
| Published in: | Liver international Vol. 40; no. 6; pp. 1344 - 1355 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.06.2020
|
| Subjects: | |
| ISSN: | 1478-3223, 1478-3231, 1478-3231 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
Methods
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.
Results
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).
Conclusion
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. |
|---|---|
| AbstractList | Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta-analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.
A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The abstracts obtained from the search were reviewed by two investigators who chose manuscripts for full-text review. The event rates were calculated with a random-effects model and quality-effects model.
The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person-years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05-4.75, I
= 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09-1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00-1.02).
The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. Background & AimsTamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.MethodsA systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The abstracts obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model.ResultsThe search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02).ConclusionThe use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta-analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.BACKGROUND & AIMSTamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta-analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients.A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The abstracts obtained from the search were reviewed by two investigators who chose manuscripts for full-text review. The event rates were calculated with a random-effects model and quality-effects model.METHODSA systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The abstracts obtained from the search were reviewed by two investigators who chose manuscripts for full-text review. The event rates were calculated with a random-effects model and quality-effects model.The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person-years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05-4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09-1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00-1.02).RESULTSThe search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person-years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05-4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09-1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00-1.02).The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia.CONCLUSIONThe use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. Background & Aims Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate the prevalence and incidence of fatty liver developed after tamoxifen treatment in breast cancer patients. Methods A systematic search of PubMed (Medline), EMBASE, OVID Medline, the Cochrane Library and other databases was performed for this review. The s obtained from the search were reviewed by two investigators who chose manuscripts for full‐text review. The event rates were calculated with a random‐effects model and quality‐effects model. Results The search yielded 165 references. Of these, 24 were included in the quantitative summary. We analysed the data of a total of 6,962 patients treated with tamoxifen and 975 patients not treated with tamoxifen. The prevalence of fatty liver among patients with breast cancer taking tamoxifen was 40.25 per 100 patients and the incidence rate was 12.37 per 100 person‐years. The incidence of fatty liver was much higher in the tamoxifen group than in the control group [incidence rate ratio: 3.12, 95% CI (confidence interval): 2.05‐4.75, I2 = 61%], regardless of region. The main risk factors were body mass index (BMI) [hazard ratio (HR): 1.15, 95% CI: 1.09‐1.22] and hypercholesterolaemia (HR: 1.01, 95% CI: 1.00‐1.02). Conclusion The use of tamoxifen was associated with increased risks in the incidence and prevalence of fatty liver, especially in patients with high BMI and hypercholesterolaemia. |
| Author | Kim, Sang Gyune Jeong, Soung Won Jung, Eun‐Ae Lee, Sae Hwan Jun, Baek Gyu Lee, Bora Yoo, Jeong‐Ju Kim, Hong Soo Kim, Young Don Cheon, Gab Jin Lee, Cheon‐Beom Kim, Young Seok Jang, Jae Young |
| Author_xml | – sequence: 1 givenname: Bora orcidid: 0000-0002-6322-5712 surname: Lee fullname: Lee, Bora organization: Graduate School of Chung‐Ang University – sequence: 2 givenname: Eun‐Ae surname: Jung fullname: Jung, Eun‐Ae organization: Soonchunhyang University Bucheon Hospital – sequence: 3 givenname: Jeong‐Ju orcidid: 0000-0002-7802-0381 surname: Yoo fullname: Yoo, Jeong‐Ju email: puby17@naver.com organization: Soonchunhyang University School of Medicine Bucheon Hospital – sequence: 4 givenname: Sang Gyune orcidid: 0000-0001-8694-777X surname: Kim fullname: Kim, Sang Gyune email: mcnulty@schmc.ac.kr organization: Soonchunhyang University School of Medicine Bucheon Hospital – sequence: 5 givenname: Cheon‐Beom surname: Lee fullname: Lee, Cheon‐Beom organization: Soonchunhyang University School of Medicine Bucheon Hospital – sequence: 6 givenname: Young Seok orcidid: 0000-0002-7113-3623 surname: Kim fullname: Kim, Young Seok organization: Soonchunhyang University School of Medicine Bucheon Hospital – sequence: 7 givenname: Soung Won orcidid: 0000-0003-2855-6011 surname: Jeong fullname: Jeong, Soung Won organization: Soonchunhyang University School of Medicine – sequence: 8 givenname: Jae Young orcidid: 0000-0001-5335-752X surname: Jang fullname: Jang, Jae Young organization: Soonchunhyang University School of Medicine – sequence: 9 givenname: Sae Hwan orcidid: 0000-0001-8320-5914 surname: Lee fullname: Lee, Sae Hwan organization: Soonchunhyang University School of Medicine – sequence: 10 givenname: Hong Soo orcidid: 0000-0003-3966-9302 surname: Kim fullname: Kim, Hong Soo organization: Soonchunhyang University School of Medicine – sequence: 11 givenname: Baek Gyu orcidid: 0000-0003-4693-9542 surname: Jun fullname: Jun, Baek Gyu organization: Gangneung Asan Hospital – sequence: 12 givenname: Young Don orcidid: 0000-0001-9003-9862 surname: Kim fullname: Kim, Young Don organization: Gangneung Asan Hospital – sequence: 13 givenname: Gab Jin surname: Cheon fullname: Cheon, Gab Jin organization: Gangneung Asan Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32170895$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc9u1DAQxi1URNuFAy-ALHEBiW3j2Emc3qqKP5VWggNwjWbtiXBx7GJ7W3LjzIln5EmY7ZYeKoEPnrH1-2ZG3xyyvRADMvZUVEeCzrF3V0dCKakesAOhOr2UtRR7d3kt99lhzhdVJfq-EY_YvqxFV-m-OWA_PyS8Ao_B4CvugnF2m3IIlieXv_IRTIkp8zjyAlP87kYMv3_8SuihoOU0CL3Am_glemcIL2XmNA8mbl1GyHjCT3mec8EJChHUzuH1TYMJC2zVAfycXX7MHo7gMz65jQv26c3rj2fvlqv3b8_PTldLo0Svlo0RphlNX62xbittUButobYNBblWTVMbCcaOfW23WUd_ulOtrQHWrW6VXLAXu7qXKX7bYC7D5LJB7yFg3OShll0nyUy6F-z5PfQibhLNS5SqOq1a0Qiint1Sm_WEdrhMboI0D39dJuDlDjAp5pxwvENENWw3OJBjw80GiT2-xxpXyLkYSgLn_6e4dh7nf5ceVuefd4o_61ew4g |
| CitedBy_id | crossref_primary_10_1210_endocr_bqaa134 crossref_primary_10_1016_j_cbi_2022_110091 crossref_primary_10_33448_rsd_v14i9_49477 crossref_primary_10_1177_00033197241308045 crossref_primary_10_1111_fcp_12720 crossref_primary_10_1016_j_jhep_2022_09_020 crossref_primary_10_1093_toxres_tfac043 crossref_primary_10_3390_genes14081653 crossref_primary_10_1371_journal_pone_0236506 crossref_primary_10_1007_s00210_025_04047_5 crossref_primary_10_1016_j_ijpharm_2024_125048 crossref_primary_10_1590_acb396924 crossref_primary_10_1080_19390211_2025_2465412 |
| Cites_doi | 10.1016/j.jfma.2015.05.006 10.1056/NEJM198902233200802 10.1016/j.jhep.2019.02.014 10.1007/BF02220448 10.3748/wjg.14.2474 10.1016/j.breast.2016.04.017 10.1016/S0140-6736(97)11423-4 10.1016/j.ajg.2011.01.003 10.1007/s11894-009-0008-4 10.1186/s13053-017-0075-8 10.1016/S1047-2797(00)00169-1 10.1016/j.cgh.2018.05.057 10.1097/EDE.0b013e31815c24e7 10.1023/A:1023348021773 10.1194/jlr.M600148-JLR200 10.1185/030079902125001308 10.1097/MD.0000000000001718 10.1016/j.clbc.2017.11.010 10.1016/S0140-6736(05)78493-2 10.2169/internalmedicine.41.345 10.1007/s12032-007-0034-8 10.1111/cas.12474 10.3923/pjbs.2020.173.180 10.1016/S0140-6736(05)76071-2 10.1097/00042737-200406000-00013 10.2214/ajr.180.1.1800129 10.1517/14740338.6.1.1 10.2217/fon.13.168 10.1097/01.cad.0000215056.47695.92 10.1016/j.ejca.2017.05.002 10.1517/14622416.3.2.229 10.1016/j.clbc.2016.12.004 10.17795/ajmb-27160 10.1016/S0140-6736(12)61963-1 10.1136/bmj.38391.663287.E0 10.1002/cncr.24374 10.1186/2050-6511-15-27 10.1002/hep.23813 10.1016/j.cdp.2007.10.004 10.1016/j.hepres.2005.09.030 |
| ContentType | Journal Article |
| Copyright | 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. 2020 John Wiley & Sons A/S |
| Copyright_xml | – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. – notice: 2020 John Wiley & Sons A/S |
| DBID | AAYXX CITATION NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
| DOI | 10.1111/liv.14434 |
| DatabaseName | CrossRef PubMed Biotechnology Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed Genetics Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1478-3231 |
| EndPage | 1355 |
| ExternalDocumentID | 32170895 10_1111_liv_14434 LIV14434 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Soonchunhyang University |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 29L 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X NPM 7QO 7T5 7U9 8FD FR3 H94 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c4194-5c1c5fc90be2608ce8c88a2d5c883b4552c3acdf92d2c3a73b48746d2aab68643 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000525084600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1478-3223 1478-3231 |
| IngestDate | Wed Oct 01 09:45:24 EDT 2025 Tue Oct 07 07:13:46 EDT 2025 Wed Feb 19 02:31:13 EST 2025 Sat Nov 29 06:22:29 EST 2025 Tue Nov 18 20:55:48 EST 2025 Wed Jan 22 16:35:24 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | fatty liver incidence risk factor tamoxifen |
| Language | English |
| License | 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4194-5c1c5fc90be2608ce8c88a2d5c883b4552c3acdf92d2c3a73b48746d2aab68643 |
| Notes | Funding information This work was supported by the Soonchunhyang University research fund. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-3966-9302 0000-0001-8694-777X 0000-0001-8320-5914 0000-0003-4693-9542 0000-0002-7802-0381 0000-0001-9003-9862 0000-0003-2855-6011 0000-0001-5335-752X 0000-0002-7113-3623 0000-0002-6322-5712 |
| PMID | 32170895 |
| PQID | 2407846151 |
| PQPubID | 2045125 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2377343477 proquest_journals_2407846151 pubmed_primary_32170895 crossref_primary_10_1111_liv_14434 crossref_citationtrail_10_1111_liv_14434 wiley_primary_10_1111_liv_14434_LIV14434 |
| PublicationCentury | 2000 |
| PublicationDate | June 2020 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: June 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Liver international |
| PublicationTitleAlternate | Liver Int |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2019; 70 2017; 82 2015; 3 2005; 330 2015; 94 2008; 19 2006; 17 2000; 7 2019; 17 2003; 79 2008; 14 2002; 3 2011; 12 2003; 19 2007; 31 2013; 381 2017; 9 2009; 115 2003; 10 1998; 351 2002; 49 2009; 11 1995; 40 2014; 105 2018; 18 2009; 10 2002; 41 2017; 15 2004; 16 2017; 17 2000; 10 2006; 47 1989; 320 2014; 15 2007; 6 2005; 32 2003; 180 2020; 23 2016; 115 1999; 354 2016; 28 2005; 33 2007; 24 2010; 52 2014; 10 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 Murata Y (e_1_2_9_14_1) 2000; 7 Ashraf M (e_1_2_9_25_1) 2009; 10 Wickramage I (e_1_2_9_33_1) 2017; 9 e_1_2_9_38_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_41_1 e_1_2_9_42_1 e_1_2_9_20_1 e_1_2_9_40_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_46_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Murata Y (e_1_2_9_18_1) 2003; 10 Nagaie T (e_1_2_9_21_1) 2005; 32 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_27_1 e_1_2_9_29_1 Coskun U (e_1_2_9_15_1) 2002; 49 |
| References_xml | – volume: 3 start-page: 5 issue: 1 year: 2015 end-page: 27160 article-title: Therapeutic effect of plant extract on tamoxifen‐induced fatty liver in rats publication-title: Avicenna J Med Biochem – volume: 115 start-page: 411 issue: 6 year: 2016 end-page: 417 article-title: Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients publication-title: J Formos Med Assoc – volume: 19 start-page: 47 issue: 1 year: 2003 end-page: 50 article-title: Serum leptin levels are associated with tamoxifen‐induced hepatic steatosis publication-title: Curr Med Res Opin – volume: 9 start-page: 111 year: 2017 end-page: 120 article-title: CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study publication-title: Breast Cancer – volume: 10 start-page: 463 issue: 7 year: 2000 end-page: 464 article-title: Racial differences in tamoxifen metabolism publication-title: Ann Epidemiol – volume: 52 start-page: 1258 issue: 4 year: 2010 end-page: 1265 article-title: Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis publication-title: Hepatology – volume: 351 start-page: 1451 issue: 9114 year: 1998 end-page: 1467 article-title: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group publication-title: Lancet – volume: 17 start-page: 709 issue: 6 year: 2006 end-page: 713 article-title: Fatty liver and transaminase changes with adjuvant tamoxifen therapy publication-title: Anticancer Drugs – volume: 354 start-page: 1299 issue: 9186 year: 1999 end-page: 1300 article-title: Non‐alcoholic steatohepatitis publication-title: Lancet – volume: 381 start-page: 805 issue: 9869 year: 2013 end-page: 816 article-title: Long‐term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor‐positive breast cancer: ATLAS, a randomised trial publication-title: Lancet – volume: 115 start-page: 3189 issue: 14 year: 2009 end-page: 3195 article-title: The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer publication-title: Cancer – volume: 19 start-page: 94 issue: 1 year: 2008 end-page: 100 article-title: A quality‐effects model for meta‐analysis publication-title: Epidemiology – volume: 320 start-page: 479 issue: 8 year: 1989 end-page: 484 article-title: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumors publication-title: The New England journal of medicine – volume: 28 start-page: 67 year: 2016 end-page: 72 article-title: Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients publication-title: Breast – volume: 79 start-page: 11 issue: 1 year: 2003 end-page: 16 article-title: Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction publication-title: Breast Cancer Res Treat – volume: 15 start-page: 27 year: 2014 article-title: Uridine prevents tamoxifen‐induced liver lipid droplet accumulation publication-title: BMC Pharmacol Toxicol – volume: 41 start-page: 345 issue: 5 year: 2002 end-page: 350 article-title: Tamoxifen‐induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen publication-title: Intern Med – volume: 24 start-page: 367 issue: 4 year: 2007 end-page: 371 article-title: A case‐control study of non‐alcoholic fatty liver disease in breast cancer publication-title: Med Oncol – volume: 82 start-page: 103 year: 2017 end-page: 114 article-title: Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: a propensity score‐matched cohort study publication-title: Eur J Cancer – volume: 10 start-page: 107 issue: 1 year: 2014 end-page: 122 article-title: Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy publication-title: Future Oncol – volume: 11 start-page: 50 issue: 1 year: 2009 end-page: 55 article-title: Nonalcoholic fatty liver disease and cardiovascular risk publication-title: Curr Gastroenterol Rep – volume: 70 start-page: 1222 issue: 6 year: 2019 end-page: 1261 article-title: Electronic address eee, Clinical Practice Guideline Panel C, Panel m, representative EGB. EASL Clinical Practice Guidelines: drug‐induced liver injury publication-title: J Hepatol – volume: 10 start-page: 609 issue: 4 year: 2009 end-page: 612 article-title: Tamoxifen use in Indian women–adverse effects revisited publication-title: Asian Pac J Cancer Prev – volume: 180 start-page: 129 issue: 1 year: 2003 end-page: 134 article-title: Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy publication-title: Am J Roentgenol – volume: 18 start-page: e677 issue: 4 year: 2018 end-page: e685 article-title: Prevention of tamoxifen‐related nonalcoholic fatty liver disease in breast cancer patients publication-title: Clin Breast Cancer – volume: 330 start-page: 932 issue: 7497 year: 2005 article-title: Incidence and risk factors for non‐alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial publication-title: BMJ – volume: 6 start-page: 1 issue: 1 year: 2007 end-page: 4 article-title: Tamoxifen‐induced non‐alcoholic steatohepatitis: where are we now and where are we going? publication-title: Expert Opinion Drug Safety – volume: 10 start-page: 97 issue: 1 year: 2003 end-page: 100 article-title: Tamoxifen‐induced non‐alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis publication-title: Oncol Rep – volume: 12 start-page: 34 issue: 1 year: 2011 end-page: 36 article-title: Incidence and risk factors for non‐alcoholic steatohepatitis in females treated with tamoxifen for breast cancer publication-title: Arab J Gastroenterol – volume: 105 start-page: 1182 issue: 9 year: 2014 end-page: 1188 article-title: A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer publication-title: Cancer Sci – volume: 31 start-page: 384 issue: 5 year: 2007 end-page: 390 article-title: Profiles of tamoxifen‐related side effects by race and smoking status in women with breast cancer publication-title: Cancer Detect Prev – volume: 3 start-page: 229 issue: 2 year: 2002 end-page: 243 article-title: CYP2D6 allele frequency in European Caucasians, Asians. Africans and their descendants publication-title: Pharmacogenomics – volume: 7 start-page: 1299 issue: 6 year: 2000 end-page: 1304 article-title: Unrecognized hepatic steatosis and non‐alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients publication-title: Oncol Rep – volume: 17 start-page: 195 issue: 3 year: 2017 end-page: 203 article-title: The relationship between tamoxifen‐associated nonalcoholic fatty liver disease and the prognosis of patients with early‐stage breast cancer publication-title: Clin Breast Cancer – volume: 49 start-page: 61 issue: 1 year: 2002 end-page: 64 article-title: Tamoxifen therapy and hepatic steatosis publication-title: Neoplasma – volume: 32 start-page: 1925 issue: 12 year: 2005 end-page: 1928 article-title: Changes in hepatic parenchymal ultrasound images in tamoxifen medication patients publication-title: Gan To Kagaku Ryoho – volume: 351 start-page: 725 issue: 9104 year: 1998 article-title: Tamoxifen‐induced fatty liver in patients with breast cancer publication-title: Lancet – volume: 16 start-page: 593 issue: 6 year: 2004 end-page: 598 article-title: Tamoxifen induced hepatotoxicity in breast cancer patients with pre‐existing liver steatosis publication-title: Eur J Gastroenterol Hepatol – volume: 47 start-page: 2223 issue: 10 year: 2006 end-page: 2232 article-title: Causes and prevention of tamoxifen‐induced accumulation of triacylglycerol in rat liver publication-title: J Lipid Res – volume: 14 start-page: 2474 issue: 16 year: 2008 end-page: 2486 article-title: Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment publication-title: World J Gastroenterol – volume: 33 start-page: 178 issue: 2 year: 2005 end-page: 180 article-title: CYP17 polymorphism and tamoxifen‐induced hepatic steatosis publication-title: Hepatol Res – volume: 17 start-page: 748 issue: 4 year: 2019 end-page: 755.e3 article-title: Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates publication-title: Clinical Gastroenterol Hepatol – volume: 15 start-page: 14 year: 2017 article-title: Motivators and barriers of tamoxifen use as risk‐reducing medication amongst women at increased breast cancer risk: a systematic literature review publication-title: Hereditary Cancer Clinical Pract – volume: 94 issue: 40 year: 2015 article-title: Selective estrogen receptor modulator‐associated nonalcoholic fatty liver disease improved survival in patients with breast cancer: a retrospective cohort analysis publication-title: Medicine (Baltimore) – volume: 23 start-page: 173 issue: 2 year: 2020 end-page: 180 article-title: Effect of distilled water on tamoxifen‐treated male wistar rats publication-title: Pakistan J Biolog Sci – volume: 40 start-page: 2602 issue: 12 year: 1995 end-page: 2607 article-title: Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy publication-title: Dig Dis Sci – ident: e_1_2_9_29_1 doi: 10.1016/j.jfma.2015.05.006 – ident: e_1_2_9_2_1 doi: 10.1056/NEJM198902233200802 – volume: 10 start-page: 97 issue: 1 year: 2003 ident: e_1_2_9_18_1 article-title: Tamoxifen‐induced non‐alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis publication-title: Oncol Rep – ident: e_1_2_9_7_1 doi: 10.1016/j.jhep.2019.02.014 – volume: 32 start-page: 1925 issue: 12 year: 2005 ident: e_1_2_9_21_1 article-title: Changes in hepatic parenchymal ultrasound images in tamoxifen medication patients publication-title: Gan To Kagaku Ryoho – ident: e_1_2_9_10_1 doi: 10.1007/BF02220448 – ident: e_1_2_9_42_1 doi: 10.3748/wjg.14.2474 – ident: e_1_2_9_30_1 doi: 10.1016/j.breast.2016.04.017 – ident: e_1_2_9_3_1 doi: 10.1016/S0140-6736(97)11423-4 – ident: e_1_2_9_26_1 doi: 10.1016/j.ajg.2011.01.003 – ident: e_1_2_9_9_1 doi: 10.1007/s11894-009-0008-4 – ident: e_1_2_9_43_1 doi: 10.1186/s13053-017-0075-8 – ident: e_1_2_9_37_1 doi: 10.1016/S1047-2797(00)00169-1 – ident: e_1_2_9_35_1 doi: 10.1016/j.cgh.2018.05.057 – ident: e_1_2_9_11_1 doi: 10.1097/EDE.0b013e31815c24e7 – ident: e_1_2_9_40_1 doi: 10.1023/A:1023348021773 – ident: e_1_2_9_47_1 doi: 10.1194/jlr.M600148-JLR200 – ident: e_1_2_9_17_1 doi: 10.1185/030079902125001308 – ident: e_1_2_9_28_1 doi: 10.1097/MD.0000000000001718 – ident: e_1_2_9_31_1 doi: 10.1016/j.clbc.2017.11.010 – ident: e_1_2_9_12_1 doi: 10.1016/S0140-6736(05)78493-2 – ident: e_1_2_9_16_1 doi: 10.2169/internalmedicine.41.345 – ident: e_1_2_9_24_1 doi: 10.1007/s12032-007-0034-8 – ident: e_1_2_9_27_1 doi: 10.1111/cas.12474 – volume: 9 start-page: 111 year: 2017 ident: e_1_2_9_33_1 article-title: CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study publication-title: Breast Cancer – volume: 49 start-page: 61 issue: 1 year: 2002 ident: e_1_2_9_15_1 article-title: Tamoxifen therapy and hepatic steatosis publication-title: Neoplasma – ident: e_1_2_9_45_1 doi: 10.3923/pjbs.2020.173.180 – ident: e_1_2_9_13_1 doi: 10.1016/S0140-6736(05)76071-2 – ident: e_1_2_9_20_1 doi: 10.1097/00042737-200406000-00013 – ident: e_1_2_9_19_1 doi: 10.2214/ajr.180.1.1800129 – volume: 10 start-page: 609 issue: 4 year: 2009 ident: e_1_2_9_25_1 article-title: Tamoxifen use in Indian women–adverse effects revisited publication-title: Asian Pac J Cancer Prev – ident: e_1_2_9_8_1 doi: 10.1517/14740338.6.1.1 – volume: 7 start-page: 1299 issue: 6 year: 2000 ident: e_1_2_9_14_1 article-title: Unrecognized hepatic steatosis and non‐alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients publication-title: Oncol Rep – ident: e_1_2_9_38_1 doi: 10.2217/fon.13.168 – ident: e_1_2_9_23_1 doi: 10.1097/01.cad.0000215056.47695.92 – ident: e_1_2_9_32_1 doi: 10.1016/j.ejca.2017.05.002 – ident: e_1_2_9_39_1 doi: 10.1517/14622416.3.2.229 – ident: e_1_2_9_34_1 doi: 10.1016/j.clbc.2016.12.004 – ident: e_1_2_9_44_1 doi: 10.17795/ajmb-27160 – ident: e_1_2_9_4_1 doi: 10.1016/S0140-6736(12)61963-1 – ident: e_1_2_9_5_1 doi: 10.1136/bmj.38391.663287.E0 – ident: e_1_2_9_6_1 doi: 10.1002/cncr.24374 – ident: e_1_2_9_46_1 doi: 10.1186/2050-6511-15-27 – ident: e_1_2_9_41_1 doi: 10.1002/hep.23813 – ident: e_1_2_9_36_1 doi: 10.1016/j.cdp.2007.10.004 – ident: e_1_2_9_22_1 doi: 10.1016/j.hepres.2005.09.030 |
| SSID | ssj0019951 |
| Score | 2.3806694 |
| Snippet | Background & Aims
Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate... Tamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta-analysis was to evaluate the prevalence... Background & AimsTamoxifen is associated with an increased risk of developing fatty liver. The aim of this systematic review and meta‐analysis was to evaluate... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1344 |
| SubjectTerms | Body mass Body mass index Body size Breast cancer Confidence intervals Fatty liver incidence Liver Liver diseases Meta-analysis Risk analysis risk factor Risk factors Searching Systematic review Tamoxifen |
| Title | Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.14434 https://www.ncbi.nlm.nih.gov/pubmed/32170895 https://www.proquest.com/docview/2407846151 https://www.proquest.com/docview/2377343477 |
| Volume | 40 |
| WOSCitedRecordID | wos000525084600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1478-3231 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0019951 issn: 1478-3223 databaseCode: DRFUL dateStart: 20030101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1da9RAcGivIn2p2vpxWssqIj4YyCW7ya4-HeqhUIuIlXsLm_2Ag7tc6aXFvvXZJ3-jv8SZzV60qCD4lE0yyW6yMzufOwPwxPLUZyZXCbJWm_BCZIkuRjoRPNfOa2cV16HYRHl0JKdT9WEDXq73wnT5IXqDG1FGWK-JwHW9-oXI57Nz8kzmfBO2MsRbMYCt1x8nx4e9E0GpUH1xxCkCANlgTCxEgTz9w1fZ0W8y5lWRNfCcyY3_Gu1N2ImiJht3uHELNlyzC3vjBtXsxQV7ykLwZ7Cq78L199HHvgdfKauTDnuRnjOyxIeqo0w3llEcOosVetjSs1Yvll9m3jXfL7-FTTHOsmZJZ7qrvDszCN62F2xO4R8seoNesDH7mUGadbtnQgcL12p6OmZKuQ3HkzefXr1NYsWGxPCR4okwIyO8UWntUE-Sxkkjpc6swENecyEQLbSxXmWWWiVekyUvbKZ1XUgUju7AAIfp7gET0npcez1qywWXRVEjMtWp0CgSptx7MYRn64mrTExnTlU15tVarcEvq8IvH8LjHvSky-HxJ6D99exXkYxXFam7KKChVDSER_1tJEDyqujGLc8QJi_LHF9QlkO422FN30uOCl8qFQ02IMffu68O330Ojfv_DvoAtjPS_oNNaB8G7emZewjXzHk7W50ewGY5lQeRJn4Apa4SuQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcFRaBFx4tEAXChiEEAciZRM7sRGXFbAqYrtCqEW9RY4f0kq72apNK3rjzIlv5EuYcbyBCpCQOMVOxrETz9jz8gzAU8tTn5lcJbi12oQXIkt0MdSJ4Ll2XjuruA7JJsrpVB4eqg9r8Gp1FqaLD9Er3IgywnpNBE4K6V-ofD47I9Nkzi_BBkc0QvzeePNxfDDprQhKhfSLQ04uALgPxshC5MnTN764H_3GZF7kWcOmM77xf8O9Cdcjs8lGHXbcgjXXbMLWqEFBe3HOnrHg_hn06ptwZS9a2bfgK8V10uE00gtGuviQd5TpxjLyRGcxRw9betbqxfLzzLvm-5dv4ViMs6xZUk13uXdnBsHb9pzNyQGERXvQSzZiP2NIs-78TOhg4VpNrWOslNtwMH67_3o3iTkbEsOHiifCDI3wRqW1Q0lJGieNlDqzAi95zYVAxNDGepVZKpV4T5a8sJnWdSGRPboD6zhMtw1MSOtx9fUoLxdcFkWN6FSnQiNTmHLvxQCer2auMjGgOeXVmFcrwQa_rAq_fABPetCjLorHn4B2VtNfRUI-qUjgRRYN-aIBPO4fIwmSXUU3bnmKMHlZ5viCshzA3Q5t-l5yFPlSqWiwATv-3n01efcpFO79O-gjuLq7vzfB-vT9fbiWkS4gaIh2YL09PnUP4LI5a2cnxw8jafwAiVwVwQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcFS2qOLCo-WxtIBBCHEgUjaxExtxWVFWIMqqQhT1Fjl-SCvtZqs2reiNMye-kS_pjOMNVICExCl2Mo6deMael2cAnlqe-szkKsGt1Sa8EFmii5FOBM-189pZxXVINlFOp_LwUO2vwavVWZguPkSvcCPKCOs1Ebg7sv4XKp_Pzsg0mfMrsM4picwA1nc_Tg72eiuCUiH94oiTCwDugzGyEHny9I0v70e_MZmXedaw6Uxu_N9wb8L1yGyycYcdt2DNNZuwNW5Q0F6cs2csuH8GvfombHyIVvYt-EZxnXQ4jfSCkS4-5B1lurGMPNFZzNHDlp61erH8MvOu-fH1ezgW4yxrllTTXe7dmUHwtj1nc3IAYdEe9JKN2c8Y0qw7PxM6WLhWU-sYK-U2HEzefHr9Nok5GxLDR4onwoyM8EaltUNJSRonjZQ6swIvec2FQMTQxnqVWSqVeE-WvLCZ1nUhkT26AwMcprsHTEjrcfX1KC8XXBZFjehUp0IjU5hy78UQnq9mrjIxoDnl1ZhXK8EGv6wKv3wIT3rQoy6Kx5-AdlbTX0VCPqlI4EUWDfmiITzuHyMJkl1FN255ijB5Web4grIcwt0ObfpechT5UqlosAE7_t59tffucyjc_3fQR7CxvzvB6vT9NlzLSBUQFEQ7MGiPT90DuGrO2tnJ8cNIGRf2xBU8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence%2C+incidence+and+risk+factors+of+tamoxifen-related+non-alcoholic+fatty+liver+disease%3A+A+systematic+review+and+meta-analysis&rft.jtitle=Liver+international&rft.au=Lee%2C+Bora&rft.au=Jung%2C+Eun-Ae&rft.au=Yoo%2C+Jeong-Ju&rft.au=Kim%2C+Sang+Gyune&rft.date=2020-06-01&rft.eissn=1478-3231&rft_id=info:doi/10.1111%2Fliv.14434&rft_id=info%3Apmid%2F32170895&rft.externalDocID=32170895 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon |